Salt-inducible kinase 2 (SIK2) is a centrosome kinase required for mitotic spindle formation and a potential target for ovarian cancer therapy. Here, we examine the effects of a novel small-molecule SIK2 inhibitor, ARN-3236, on sensitivity to paclitaxel in ovarian cancer.
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher copy:
- American Association for Cancer Research Publisher's website
- Clinical Cancer Research Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright date:
A novel compound ARN-3236 inhibits salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record